Wells Fargo & Company Inhibrx, Inc. Transaction History

Wells Fargo & Company

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$32.76 - $39.56 $299,164 - $361,261	-9,132 Reduced 38.67%	14,486 $506,000
Q4 2023 Feb 09, 2024	SELL	$14.5 - $38.0 $283,431 - $742,786	-19,547 Reduced 45.28%	23,618 $897,000
Q3 2023 Nov 13, 2023	SELL	$15.75 - $26.31 $58,275 - $97,347	-3,700 Reduced 7.9%	43,165 $792,000
Q2 2023 Aug 15, 2023	BUY	$16.96 - $27.82 $70,231 - $115,202	4,141 Added 9.69%	46,865 $1.22 Million
Q1 2023 May 12, 2023	BUY	$18.45 - $27.14 $650,620 - $957,064	35,264 Added 472.71%	42,724 $806,000
Q4 2022 Feb 13, 2023	SELL	$20.18 - $33.33 $27,404 - $45,262	-1,358 Reduced 15.4%	7,460 $183,000
Q3 2022 Nov 14, 2022	BUY	$11.58 - $24.73 $18,423 - $39,345	1,591 Added 22.01%	8,818 $158,000
Q2 2022 Aug 12, 2022	SELL	$8.52 - $25.26 $43,537 - $129,078	-5,110 Reduced 41.42%	7,227 $82,000
Q1 2022 May 16, 2022	SELL	$19.89 - $43.18 $207,194 - $449,806	-10,417 Reduced 45.78%	12,337 $275,000
Q4 2021 Feb 14, 2022	SELL	$26.75 - $46.02 $172,136 - $296,138	-6,435 Reduced 22.05%	22,754 $994,000
Q3 2021 Nov 15, 2021	BUY	$25.18 - $37.81 $445,484 - $668,934	17,692 Added 153.88%	29,189 $972,000
Q2 2021 Aug 16, 2021	BUY	$14.69 - $27.52 $19,302 - $36,161	1,314 Added 12.9%	11,497 $316,000
Q1 2021 May 13, 2021	SELL	$16.27 - $41.26 $180,043 - $456,583	-11,066 Reduced 52.08%	10,183 $205,000
Q4 2020 Feb 09, 2021	BUY	$15.96 - $50.0 $224,222 - $702,450	14,049 Added 195.13%	21,249 $701,000
Q3 2020 Nov 05, 2020	BUY	$16.77 - $20.65 $120,744 - $148,680	7,200 New	7,200 $130,000

18.6K

Ticker INBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,057,700
Market Cap $550M
Description
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.